| Identification | Back Directory | [Name]
KRN7000 | [CAS]
158021-47-7 | [Synonyms]
KRN7000
α-Galactosyl Ceramide
Supplier: Funakoshi Co. Ltd.
1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine
(2S,3S,4R)-1-O-(α-D-Galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol
N-[(1S,2S,3R)-1-[(α-D-Galactopyranosyloxy)Methyl]-2,3-dihydroxyheptadecyl]hexacosanaMide
α-Galactosyl CeraMideSupplier: Funakoshi Co. Ltd. | [Molecular Formula]
C50H99NO9 | [MDL Number]
MFCD00939559 | [MOL File]
158021-47-7.mol | [Molecular Weight]
858.33 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
125-130°C | [Boiling point ]
939.8±65.0 °C(Predicted) | [density ]
1.04±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Pyridine (Slightly, Heated) | [form ]
White solid. | [pka]
12.92±0.70(Predicted) | [color ]
White to Pale Beige | [Stability:]
Hygroscopic | [CAS DataBase Reference]
158021-47-7 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Galactosylceramides play an important roles in promoting the regulation of nerve cells, regulating protein kinase C activities and modulating the function of the hormone receptor. It has shown to have significant immunostimulatory and anti-umor activity | [Definition]
ChEBI: A glycophytoceramide having an alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. | [Uses]
KRN 7000 is a potent synthetic α-galactosylceramide, which, in association with the antigen-presenting CD1d protein, activates NKT immune cells. As these cells have important roles in the rejection of malignant tumors and in the regulation of several autoimmune diseases, KRN 7000 has activity in many diseases, including cancer, lupus, diabetes, malaria, and tuberculosis. | [Description]
KRN 7000 is a potent synthetic α-galactosylceramide, which, in association with the antigen-presenting CD1d protein, activates NKT immune cells.1,2 As these cells have important roles in the rejection of malignant tumors and in the regulation of several autoimmune diseases, KRN 7000 has activity in many diseases, including cancer, lupus, diabetes, malaria, and tuberculosis.3,4,5 | [storage]
Store at -20°C | [References]
[1] H. J. J. VAN DER VLIET. Effects of α-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Vα24+ Vβ11+ T cells[J]. Immunology, 2001, 98 4: 557-563. DOI: 10.1046/j.1365-2567.1999.00920.x
[2] NOEMI A. SAAVEDRA-AVILA, AMY R. HOWELL* A Humanized Mouse Model Coupled with Computational Analysis Identifies Potent Glycolipid Agonist of Invariant NKT Cells[J]. ACS Chemical Biology, 2024, 19 4: 926-937. DOI: 10.1021/acschembio.3c00736
[3] DEYING YANG . Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development[J]. Acta Pharmaceutica Sinica. B, 2022, 12 12: Pages 4432-4445. DOI: 10.1016/j.apsb.2022.05.028 |
|
|